Aktienanalyse zu Kardigan Inc (KARD)KARDKardigan Inc

Kardigan, Inc. is a clinical-stage precision therapeutics company. It is developing medicines that target the root cause of specific cardiovascular diseases where no approved treatments exist. Its pipeline of products includes Danicamtiv, Ataciguat and Tonlamarsen. Danicamtiv is an investigational oral cardiac atrial and ventricular myosin activator for the treatment of genetic dilated cardiomyopathy caused by pathogenic variants in myosin heavy chain 7 (MYH7) and titin, the common sarcomeric gene variants. Ataciguat is an investigational oral, once-daily soluble guanylate cyclase activator aimed at slowing the progression of calcific aortic valve stenosis in patients with moderate diseases. Tonlamarsen is an investigational liver-directed antisense oligonucleotide administered once-monthly via subcutaneous injection, targeting hepatic angiotensinogen for the management of blood pressure in acute severe hypertension post-hospitalization. Prolaio is a clinical intelligence platform. It operates in the Healthcare sector.

Kardigan Inc is not a good buy right now due to significant financial losses and negative performance trends. The stock currently trades at $13.03, down 21.69% over the past 20 days, and has an RSI of 34.936, indicating it's oversold. The company reported a staggering net loss of $116.236 million in Q2 2026, raising concerns about its financial health. While UBS has a price target of $25, the recent downgrade by JPMorgan to $46 suggests caution. The main risk is the company's negative equity of $300.626 million in Q1 2026, which could impact its long-term viability.